BioWorld

Oct. 8, 2007

MAP's IPO Prices Lower Than Expected But Still Raises $60M

MAP Pharmaceuticals Inc. is adding $60 million through an initial public offering to support an upcoming Phase III trial of its late-stage aerosolized products for asthma and migraine. (BioWorld Today) Read More

Haptogen Acquisition Brings Shark Therapies To Wyeth

Academia May Be Suffering But Biotech Chugs Along

Targeting Cellular MicroRNA Can Flush HIV Out Of Hiding

Pfizer Launches Bay Area Biotech Innovation Center

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 17, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

For clonal hematopoiesis, epigenetics can be in driver’s seat

BioWorld Science

Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...

Illustration of amyloid plaques in Alzheimer's disease

Elixiron’s enrupatinib shows upbeat interim phase II AD results

BioWorld

Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...

Gene replacement rescues autism-related phenotypes in mice

BioWorld Science

Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...